
Korea’s Celltrion Healthcare (Kosdaq: 068270) has launched the first subcutaneous (SC) formulation of infliximab for rheumatoid arthritis in the UK.
The product, Remsima, is a biosimilar of Johnson & Johnson's (NYSE: JNJ) Remicade, and was approved in this indication in the European Union in November of last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze